CJC-1295

Mechanism

CJC-1295 acts as an agonist at growth hormone-releasing hormone (GHRH) receptors on the anterior pituitary. By mimicking endogenous GHRH, it stimulates the pulsatile release of growth hormone (GH), which in turn stimulates hepatic production of insulin-like growth factor 1 (IGF-1). The DAC (drug affinity complex) modification — where present — binds to serum albumin, extending the peptide's half-life from ~30 minutes (without DAC) to approximately 8 days (with DAC). Unlike exogenous recombinant GH, CJC-1295 preserves the natural pulsatile pattern of GH release, which may reduce the risk of feedback inhibition and desensitisation observed with continuous GH elevation. (Teichman et al., 2006; Ionescu & Frohman, 2006)

Evidence base

Human Evidence

The primary human study is the Phase I trial by Teichman et al. (2006), which showed dose-dependent IGF-1 elevations lasting up to 14 days after a single administration of CJC-1295 with DAC in healthy adults. No serious adverse events were reported at the doses studied. A companion study (Ionescu & Frohman, 2006) confirmed that pulsatile GH secretion is preserved during continuous stimulation with CJC-1295, which is a key mechanistic distinction from exogenous rhGH. A small open-label study in HIV-associated lipodystrophy was presented as a conference abstract (Bhatt et al., 2006) but has not been published as a full peer-reviewed paper.

Animal Evidence

Studies in rodents and swine have demonstrated increased GH and IGF-1 levels, with some evidence of changes in lean body mass and sleep architecture. These findings are preliminary and should not be extrapolated to human outcomes without caution.

Evidence Gaps

There are no published large-scale (Phase III) clinical trials. Long-term safety data in humans is absent. Much of the broader claims about body composition, recovery, and anti-ageing effects rest on animal models, mechanistic reasoning, or anecdote rather than robust human trial data.

Protocols

Note: These are protocols commonly discussed in research contexts, not medical dosing instructions. CJC-1295 is an unlicensed research peptide.

CJC-1295 without DAC (Modified GRF 1-29)

• Dose range: 100–300 mcg per administration
• Frequency: 1–3 times daily (subcutaneous)
• Rationale: Short half-life (~30 min) necessitates frequent dosing to coincide with natural GH pulses
• Cycle: 4–8 weeks commonly discussed

CJC-1295 with DAC

• Dose range: 1–2 mg per week
• Frequency: Once weekly (subcutaneous)
• Rationale: Extended half-life (~8 days) allows sustained IGF-1 elevation from a single dose
• Cycle: 4–8 weeks commonly discussed

Cycle and Time Off

4–8 week cycles followed by a comparable rest period are frequently discussed. There is no clinical evidence establishing optimal cycle length or recovery periods. Researchers should monitor IGF-1 and related blood markers to assess systemic effects.

UK legal status

CJC-1295 is legal to purchase and possess in the UK for research purposes. It is not classified as a controlled substance under the Misuse of Drugs Act 1971 and is not listed under the Psychoactive Substances Act 2016.

MHRA Position

CJC-1295 is not a licensed medicinal product in the UK. The MHRA regulates the sale and supply of medicinal products; selling or supplying peptides for human consumption without appropriate marketing authorisation would fall under these regulations. However, purchase and possession for bona fide laboratory or research use is permitted.

Practical Notes

• Vendors sell CJC-1295 explicitly labelled 'for research use only — not for human consumption'.
• Customs: Importing small quantities for research is generally not restricted, but quantities suggesting commercial supply may attract scrutiny.
• Regulations may change — always verify current status before purchasing.

This information is provided for educational purposes and does not constitute legal advice.

Vendor notes

CJC-1295 is widely available from UK research peptide vendors. When sourcing, look for vendors that provide third-party certificates of analysis (COAs) confirming purity and identity. The DAC and non-DAC variants are sometimes sold under different names — verify which form you are purchasing, as the dosing frequency differs significantly between them. See the Vetted UK Vendors section for approved suppliers.